AvroBio Inc (AVRO)

10% Owner Leonard Braden Michael acquire 296882 shares of AvroBio Inc [AVRO] – Knox Daily - Knox Daily

Knox Daily

Investing in AvroBio Inc (AVRO) might be an excellent idea, but the stock is currently overvalued/undervalued – US ... - US Post News

US Post News

Avrobio executive buys shares worth over $970k - Investing.com India

Investing.com India

Financial Analysis: AVROBIO (NASDAQ:AVRO) versus SOPHiA GENETICS (NASDAQ:SOPH) - Defense World

Defense World

AVROBIO, Inc. (NASDAQ:AVRO) Major Shareholder Acquires $587,191.25 in Stock - MarketBeat

MarketBeat

Investors in cash trouble should check out AvroBio Inc (AVRO) – Sete News - SETE News

SETE News

AVROBIO, Inc. (NASDAQ:AVRO) Sees Significant Growth in Short Interest - MarketBeat

MarketBeat

AVRO Stock Earnings: Avrobio Beats EPS for Q1 2024 - MSN

MSN

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWN, INBX, AVRO - The Malaysian Reserve

The Malaysian Reserve

AVROBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC ... - Business Wire

Business Wire

AVROBIO (NASDAQ:AVRO) Shares Up 1.6% - Defense World

Defense World

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc ... - GlobeNewswire

GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HireRight Holdings ... - GlobeNewswire

GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ZeroFox Holdings ... - GlobeNewswire

GlobeNewswire

Avrobio's road ends in reverse merger with Tim Springer-backed startup - Yahoo Finance

Yahoo Finance

Avrobio And Tectonic Therapeutic To Merge - Contract Pharma

Contract Pharma

Avrobio To Explore Strategic Alternatives - Contract Pharma

Contract Pharma

Avrobio stops programs, halves head count and searches for exit - Fierce Biotech

Fierce Biotech

Novartis Purchases Cystinosis Gene Therapy from AVROBIO - Pharmaceutical Technology Magazine

Pharmaceutical Technology Magazine

Novartis buys AVROBIO cystinosis gene therapy program for $87.5M - Labiotech.eu

Labiotech.eu

Avrobio agrees to sell cystinosis gene therapy to Novartis - Pharmaceutical Technology

Pharmaceutical Technology

Novartis to buy Avrobio gene therapy for $88M, leaving rest of the biotech on the shelf - Fierce Biotech

Fierce Biotech

Avrobio reports positive follow-up data for cystinosis gene therapy - Clinical Trials Arena

Clinical Trials Arena

Avrobio reports positive data from cystinosis gene therapy trial - Clinical Trials Arena

Clinical Trials Arena

Avrobio stock jumps 78% amid speculation of takeover interest - Seeking Alpha

Seeking Alpha

AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory ... - Business Wire

Business Wire

AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis - Business Wire

Business Wire

Cystinosis Pipeline Assessment | Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic ... - openPR

openPR

Avrobio receives orphan drug designation for gene therapy - Pharmaceutical Technology

Pharmaceutical Technology

UK MHRA approves Avrobio's Phase I/II Hunter syndrome therapy trial - Clinical Trials Arena

Clinical Trials Arena

Avrobio's gene therapy prompts positive phase I/II data in cystinosis - BioWorld Online

BioWorld Online

Avrobio Stopping Its Gene Therapy Program for Fabry Disease - Fabry Disease News

Fabry Disease News

Avrobio shares plummet as Fabry program axed, new trial starts slated for 2023 - Fierce Biotech

Fierce Biotech

University announces partnership with AVROBIO for Hunter syndrome gene therapy - The University of Manchester

The University of Manchester

Experts divided on Avrobio's phase two gene therapy for Fabry disease - Clinical Trials Arena

Clinical Trials Arena

AVROBIO: Promise In Fabry Disease (NASDAQ:AVRO) - Seeking Alpha

Seeking Alpha

Moving Average Crossover Alert: AVROBIO - Yahoo Lifestyle UK

Yahoo Lifestyle UK

AVROBIO, Inc. Announces Pricing of Initial Public Offering - GlobeNewswire

GlobeNewswire

Avrobio launches gene therapy program for Gaucher disease - Mass Device

Mass Device